drugset
drugset / Trial / NCT05376878

An Investigational Scan (64Cu-DOTA-Trastuzumab PET/MRI) in Imaging Patients With HER2+ Breast Cancer With Brain Metastasis

NCT05376878 ↗

Phase 4 Recruiting 10 enrolled City of Hope Medical Center National Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelDiagnostic

Summary

This clinical trial examines an investigational scan (64Cu-DOTA-trastuzumab positron emission tomography \[PET\]/magnetic resonance imaging \[MRI\]) in imaging patients with HER2+ breast cancer that has spread to the brain (brain metastasis). Diagnostic procedures, such as 64Cu-DOTA-trastuzumab PET/MRI, may help find HER2+ breast cancer that has spread to the brain and determine whether cancer in the brain takes up trastuzumab, which may predict for response to trastuzumab deruxtecan (the standard of care chemotherapy).

Timeline

Start
2022-12-21
Primary completion
2027-04-27
Completion
2027-04-27

Drugs

EvaluationDrugModalityDoseRoute
Subject Copper Cu 64-DOTA-Trastuzumab Diagnostic / imaging agent — Intravenous
Subject Trastuzumab deruxtecan Monoclonal antibody — Intravenous
Background Trastuzumab Monoclonal antibody — Intravenous

Indications

invasive breast carcinoma metastatic malignant neoplasm in the brain